Zaire ebolavirus — LLMpedia

Contents

Zaire ebolavirus is a species of filovirus responsible for multiple severe viral hemorrhagic fever outbreaks. It is a member of the family Filoviridae and is historically associated with high case fatality ratios in outbreaks affecting countries such as Democratic Republic of the Congo, Guinea, and Sierra Leone. The virus has driven major international responses involving organizations including the World Health Organization, Médecins Sans Frontières, and national public health agencies such as the Centers for Disease Control and Prevention.

Virology and taxonomy

Zaire ebolavirus belongs to the genus Ebolavirus within the family Filoviridae, alongside species such as Sudan ebolavirus, Bundibugyo ebolavirus, and Reston ebolavirus; this classification has been refined by the International Committee on Taxonomy of Viruses and reflected in publications from institutions like the National Institutes of Health and the European Centre for Disease Prevention and Control. Morphologically, virions are filamentous and pleomorphic as documented in studies from laboratories at Centers for Disease Control and Prevention and Institut Pasteur, with ultrastructure resolved by groups at Harvard University and Max Planck Institute using electron microscopy methods developed at Cambridge University. Zaire ebolavirus is phylogenetically distinguished by nucleotide divergence from related ebolaviruses in analyses performed by teams at Oxford University, University of Liverpool, and Broad Institute.

The Zaire ebolavirus genome is a nonsegmented, negative-sense single-stranded RNA of approximately 19 kilobases encoding seven structural proteins (NP, VP35, VP40, GP/sGP, VP30, VP24, L) as characterized by sequencing efforts from Sanger Institute, Wellcome Sanger Institute, and sequencing centers at Johns Hopkins University and University of California, San Francisco. Viral entry is mediated by the glycoprotein GP, with host factors such as Niemann–Pick C1 and cathepsins implicated by research groups at Yale University and Rockefeller University; studies from Cold Spring Harbor Laboratory and Massachusetts Institute of Technology elucidated transcription and replication mechanisms dependent on the L polymerase complex. Accessory proteins VP35 and VP24 antagonize innate immune signaling pathways involving Interferon regulatory factor 3, Signal transducer and activator of transcription 1, and RIG-I as shown by investigators at University of Texas Medical Branch and Imperial College London.

Epidemiological patterns for Zaire ebolavirus have been documented in outbreaks centered in regions such as Kikwit and Yambuku in what is today the Democratic Republic of the Congo, and in the 2013–2016 epidemic affecting Guinea, Liberia, and Sierra Leone; international spread prompted responses from United Nations, African Union, and nongovernmental organizations including Doctors Without Borders. Zoonotic reservoirs are believed to include several Pteropodidae fruit bat genera based on field studies by teams from University of Edinburgh, Wildlife Conservation Society, and Royal Society–supported projects; spillover events have been associated with activities documented in reports by World Health Organization and Centers for Disease Control and Prevention such as hunting, burial practices, and nosocomial transmission in facilities described in case reports from University of Kinshasa and Kenema Government Hospital. Human-to-human transmission occurs via contact with bodily fluids, contaminated fomites, and needle exposure, leading to cluster investigations by epidemiologists from London School of Hygiene and Tropical Medicine, Johns Hopkins Bloomberg School of Public Health, and Columbia University.

Clinical presentation ranges from febrile prodrome to multisystem involvement with hemorrhagic manifestations, shock, and multiorgan failure, as characterized in case series from Kenema District Hospital, Donka Hospital, and cohort studies published by researchers at Imperial College London and Harvard Medical School. Pathogenesis involves widespread viral replication, endothelial dysfunction, coagulopathy involving pathways studied by investigators at Stanford University and University of Pennsylvania, and dysregulated host immune responses elucidated by teams at University of Cambridge and Karolinska Institutet. Risk factors for severe disease include delayed care and comorbidities noted in clinical analyses from Centers for Disease Control and Prevention and observational studies conducted by Médecins Sans Frontières.

Laboratory confirmation relies on molecular diagnostics such as real-time reverse transcription PCR assays developed by Centers for Disease Control and Prevention, sequencing workflows from Wellcome Sanger Institute, and point-of-care antigen tests evaluated by World Health Organization and commercial partners including Abbott Laboratories. Serological methods including ELISA and neutralization assays have been standardized in reference laboratories at Institut Pasteur, Rocky Mountain Laboratories, and National Microbiology Laboratory (Canada). Biosafety considerations require containment at Biosafety Level 4 facilities like those at Rocky Mountain Laboratories, Porton Down, and NIID during viral isolation and high-risk manipulations.

Preventive strategies encompass infection prevention and control practices implemented in hospitals described by Hospital Universitaire de Donka and community measures supported by World Health Organization and United Nations Children's Fund programs. Therapeutics evaluated include monoclonal antibodies such as REGN-EB3 and mAb114 developed by consortia including Regeneron Pharmaceuticals and the National Institute of Allergy and Infectious Diseases, as well as antiviral remdesivir studied by teams at Gilead Sciences and clinical trial networks coordinated by WHO Solidarity Trial partners. Vaccination efforts center on the rVSV-ZEBOV vaccine produced by Merck & Co. with efficacy demonstrated in ring vaccination trials led by groups from National Institutes of Health, Guinea Ministry of Health, and Norwegian Institute of Public Health.

First recognized in 1976 near Yambuku in what was then Zaire, subsequent major outbreaks have included the 1995 Kikwit outbreak, the 2007 Kasai-Occidental clusters, and the 2013–2016 West Africa epidemic centered in Guinea, Liberia, and Sierra Leone; more recent flare-ups occurred in Democratic Republic of the Congo provinces with international coordination involving World Health Organization, International Federation of Red Cross and Red Crescent Societies, and national ministries such as the Ministry of Health (DRC). Scientific, humanitarian, and public health responses have engaged institutions including Médecins Sans Frontières, Centers for Disease Control and Prevention, Bill & Melinda Gates Foundation, and research consortia at Wellcome Trust and European Commission-funded networks to improve diagnostics, therapeutics, and vaccine deployment.